Scilex Holding Co banner
S

Scilex Holding Co
NASDAQ:SCLX

Watchlist Manager
Scilex Holding Co
NASDAQ:SCLX
Watchlist
Price: 8.97 USD 10.88% Market Closed
Market Cap: $76.2m

Relative Value

There is not enough data to reliably calculate the relative value of SCLX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SCLX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

SCLX Competitors Multiples
Scilex Holding Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Scilex Holding Co
NASDAQ:SCLX
76.2m USD 1.6 -0.5 -2 -1.9
US
Eli Lilly and Co
NYSE:LLY
952.4B USD 14.6 46.1 31.1 33.2
US
Johnson & Johnson
NYSE:JNJ
592.2B USD 6.3 22.1 15.3 18.8
CH
Roche Holding AG
SIX:ROG
284.1B CHF 4.6 30.2 12.8 14.9
CH
Novartis AG
SIX:NOVN
243.9B CHF 5.6 22.4 13.9 17.8
UK
AstraZeneca PLC
LSE:AZN
234.8B GBP 5.4 30.7 17 23.9
US
Merck & Co Inc
NYSE:MRK
298.8B USD 4.6 16.4 10.1 12.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
151.6B USD 2.4 19.5 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
125.8B USD 2.6 17.8 7.4 9.2
P/E Multiple
Earnings Growth PEG
US
S
Scilex Holding Co
NASDAQ:SCLX
Average P/E: 24
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.1
28%
1.6
US
Johnson & Johnson
NYSE:JNJ
22.1
7%
3.2
CH
Roche Holding AG
SIX:ROG
30.2
29%
1
CH
Novartis AG
SIX:NOVN
22.4
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
30.7
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.5
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
S
Scilex Holding Co
NASDAQ:SCLX
Average EV/EBITDA: 46.8
Negative Multiple: -2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.1
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.7
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
CH
Novartis AG
SIX:NOVN
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.5
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
S
Scilex Holding Co
NASDAQ:SCLX
Average EV/EBIT: 101.5
Negative Multiple: -1.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.8
7%
2.7
CH
Roche Holding AG
SIX:ROG
14.9
6%
2.5
CH
Novartis AG
SIX:NOVN
17.8
9%
2
UK
AstraZeneca PLC
LSE:AZN
23.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
3%
3.1
US
Pfizer Inc
NYSE:PFE
10
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.2
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett